HGH Fragment 176-191: The Lipolytic GH Tail Research Guide

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Written by Sophie Chen. Reviewed by Morgan Ellis, MSc Endocrinology · Last updated: 23 May 2026

HGH Fragment 176-191 — also written as HGH Frag 176-191, GH Frag, or simply “the fat-loss fragment” — is one of the most-misunderstood compounds in the entire research-peptide catalogue. It looks like growth hormone (it is a 16-amino-acid slice of the C-terminal end of HGH), it sometimes gets sold alongside HGH 191AA, and yet pharmacologically it does almost nothing that full-length HGH does. It doesn’t raise IGF-1. It doesn’t stimulate longitudinal bone growth. It doesn’t cause measurable insulin resistance. What it does — at least in the published preclinical literature — is selectively activate lipolysis in adipocytes, which is exactly why the fitness and biohacker communities adopted it as a “fat-loss without the metabolic baggage” tool.

This guide walks through what HGH Fragment 176-191 actually is at the molecular level, how its proposed mechanism differs from full-length GH and from GLP-1 agonists, what the dose-response literature shows, why it’s so often confused with AOD-9604 (the modified version), and how researchers should evaluate a vial’s Certificate of Analysis before committing to a protocol.

Important framing: Throughout this guide, “research” refers to bench, animal, or human-subject investigations conducted under appropriate ethical and regulatory oversight. HGH Fragment 176-191 is offered as a research-grade laboratory reagent (CAS 221231-10-3; HPLC-verified purity; COA-keyed lots), not as a personal-use therapeutic.

What Is HGH Fragment 176-191?

HGH Fragment 176-191 is a 16-amino-acid synthetic polypeptide whose sequence is identical to residues 176 through 191 of the full-length human growth hormone molecule — the carboxyl-terminal “tail” of the parent hormone — and which carries the molecular-weight signature of approximately 1817 daltons.

The peptide was first described in the 1990s during a research programme at Monash University in Melbourne, where Frank Ng and colleagues were dissecting which structural regions of HGH carried which biological activities. The full-length molecule has three distinct functional domains — broadly, the growth-promoting domain (responsible for GH receptor binding and IGF-1 generation), the insulin-antagonist domain, and the lipolytic domain. The research team showed that the C-terminal 16-amino-acid fragment retained essentially all of the lipolytic activity of the parent hormone while losing the growth-promoting, IGF-1-elevating, and insulin-antagonist properties.

That separation of function is the entire reason HGH Fragment 176-191 exists in the research-peptide marketplace today. If you want to study or activate adipocyte lipolysis without simultaneously raising IGF-1, suppressing insulin sensitivity, or stimulating tissue growth, the 16-mer fragment is — at least on the preclinical evidence — the cleanest compound for that question. The full hormone confounds the experiment; the fragment isolates the effect.

The relationship to AOD-9604

AOD-9604 (Anti-Obesity Drug 9604, also written Tyr-hGH 177-191) is the patented Metabolic Pharmaceuticals derivative. The molecular difference is small: AOD-9604 carries an extra N-terminal tyrosine residue attached to residues 177-191. The biological consequence is also small — both molecules engage the same proposed lipolytic mechanism — but AOD-9604 was the version Metabolic Pharmaceuticals pushed through human clinical trials in the 2000s (with mixed Phase 2b results) while plain HGH Frag 176-191 remained a research-only molecule. For procurement decisions: if a research protocol cites Metabolic Pharmaceuticals’ published data, it likely used AOD-9604 not Frag 176-191. The two are structurally similar but legally and historically distinct.

How Does HGH Fragment 176-191 Work? (Mechanism)

Growth hormone biology has been studied for over seventy years, but the lipolytic mechanism of the C-terminal fragment is genuinely separate from the well-known GH receptor / JAK2 / STAT5 / IGF-1 cascade. The fragment does not engage GH receptors. Multiple binding studies have failed to show meaningful affinity. Whatever the fragment does, it does through a different receptor or signalling pathway entirely.

The β3-adrenergic-like hypothesis

The dominant working model — proposed by Ng and refined by Heffernan et al. — is that HGH Fragment 176-191 mimics or amplifies β3-adrenergic receptor signalling on adipocytes. β3-adrenergic activation drives hormone-sensitive lipase upregulation, promotes triglyceride breakdown into free fatty acids and glycerol, and inhibits the lipogenic enzyme acetyl-CoA carboxylase. The functional outcome — in mouse adipose tissue, in human adipocytes in culture, and in early-phase human studies — is increased lipolysis, increased fatty-acid oxidation, and reduced new fat storage.

The β3 receptor is enriched in adipose tissue (brown more than white in humans), and only sparsely expressed in liver, skeletal muscle, and bone. That tissue-distribution pattern is the underlying reason HGH Fragment 176-191’s effects are adipose-targeted rather than systemic.

What’s deliberately missing from the mechanism

This is where the fragment differs sharply from full-length HGH 191AA. The fragment lacks the structural epitopes required to:

• Bind and dimerise GH receptors (no GH receptor cascade activation)
• Stimulate hepatic IGF-1 synthesis (no IGF-1 elevation on serum assays)
• Antagonise insulin (no glucose tolerance disruption in published studies)
• Stimulate epiphyseal-plate chondrocyte proliferation (no growth effect in juvenile animal models)
• Drive STAT5 transcription of GH-responsive genes

For researchers, this is the practical takeaway: HGH Fragment 176-191 is not “weaker HGH” — it is a structurally distinct molecule that happens to share sequence with the parent hormone, and engages a different downstream pathway.

Key Uses & Applications

HGH Fragment 176-191 has no formally approved indication anywhere in the world. AOD-9604 reached Phase 2b human trials for obesity in the late 2000s but did not achieve statistically significant weight loss versus placebo at the doses tested, and the development programme was discontinued. The compound therefore lives entirely in the research and biohacker spaces.

Adipose lipolysis research

The cleanest experimental application: studying fatty-acid mobilisation and oxidation kinetics in adipose tissue without confounding IGF-1 effects. Murine models consistently show measurable reductions in visceral and subcutaneous fat mass over 4–8 week dosing windows, with body-composition shifts most pronounced in animals on standardised diets. Human research data is thinner but directionally consistent.

Metabolic syndrome and lipid-profile research

Because the fragment increases free-fatty-acid oxidation without raising IGF-1, several research groups have investigated its effect on triglyceride and cholesterol parameters in dyslipidaemia models. Reported outcomes include reduced fasting triglycerides and improved HDL/LDL ratios in some preclinical work, though replication in well-powered human trials remains limited.

Combination-protocol research

HGH Fragment 176-191 is frequently paired in research protocols with compounds where IGF-1 elevation would either confound the experimental endpoint or contraindicate the design. Common pairings include:

• CJC-1295 + Ipamorelin stacks (where the fragment adds peripheral lipolysis to the GHRH/GHRP-driven systemic pulse)
• GLP-1 agonist research models (Semaglutide, Tirzepatide) where the fragment provides an adipocyte-direct mechanism complementary to the GLP-1 central appetite mechanism
• Standalone calorie-restriction model protocols

Versus pure pituitary-stimulator approaches

If a research question is about overall body composition (lean mass and fat mass), the GH-pulse pathway (Sermorelin, Tesamorelin, CJC-1295, Ipamorelin) is more appropriate. If the question is strictly about lipolysis kinetics or fat-mass reduction without the IGF-1 confounder, HGH Fragment 176-191 is the targeted choice. See our best peptides for fat loss hub for the full landscape and decision framework.

Safety Profile, Side Effects & Dosing

The side-effect profile of HGH Fragment 176-191 is the headline reason researchers favour it over full-length GH for narrowly-defined questions. The classic GH side effects — fluid retention, carpal tunnel, insulin resistance, IGF-1-mediated proliferative concerns — are all absent or substantially reduced in published studies. What’s left is a small set of mild, generally peptide-class-typical effects.

Documented side effects

Dose ranges in published literature

• Preclinical mouse/rat lipolysis research: 250–500 mcg/kg/day, typically delivered SC, divided into 1–3 doses.
• Human research (Metabolic Pharmaceuticals AOD-9604 Phase 2b): 0.5–1.0 mg/day for 12–24 weeks (these are AOD-9604 figures, used as a proxy where Frag 176-191 human data is sparse).
• Common research protocols: 250–500 mcg twice daily, pre-fasted morning and pre-bed; total daily dose 500 mcg–1 mg.
• Cycling considerations: Less concern about receptor desensitisation than with GH/GHRH-receptor agonists, but many researchers still use 4–8 week on / 2 week off cycles for protocol hygiene.

What Does the Research Say?

Qualifying language: The body of preclinical work supports a confident reading of mechanism — lipolytic activity without IGF-1 elevation is well-established in animal models and cell culture. The clinical human-trial evidence (AOD-9604 Phase 2b) did not show statistically significant weight loss at the doses tested, which is the honest answer to the question “does it actually cause weight loss in humans?”. The preclinical mechanism is real; the clinical-magnitude question remains open.

HGH Fragment 176-191 vs Alternatives — Comparison Table

How to decide

• Isolating lipolysis without IGF-1 confounder: HGH Fragment 176-191 or AOD-9604.
• Citing a specific Metabolic Pharmaceuticals published trial: AOD-9604 specifically (Frag 176-191 cannot substitute on regulatory/citation grounds).
• Want lean-mass plus fat-loss in the same research protocol: HGH 191AA or a Sermorelin/CJC-1295/Ipamorelin pulse-stimulator approach.
• Magnitude weight-loss outcomes are the primary endpoint: GLP-1 agonists (Semaglutide, Tirzepatide) outperform any GH-pathway peptide for sheer kilogram reduction.
• Stacking with GHRP/GHRH research: HGH Fragment 176-191 pairs cleanly because it doesn’t compete at the GH receptor or alter pituitary feedback.

How to Use HGH Fragment 176-191 — Practical Research Guidance

Reconstitution

HGH Fragment 176-191 ships as lyophilised powder, typically 5–10 mg per vial. Reconstitution follows the standard small-peptide protocol:

1. Allow vial to reach room temperature before opening.
2. Inject bacteriostatic water down the inside wall of the vial — never directly onto the cake — at a volume that gives a convenient concentration for the planned dosing. For a 5 mg vial, 2 mL of BAC water yields 2.5 mg/mL (250 mcg per 0.1 mL insulin-syringe unit). For 10 mg vials, 4 mL gives the same convenient concentration.
3. Swirl gently for 30–60 seconds; do not shake or invert vigorously. The 16-amino-acid fragment is more shake-tolerant than full-length HGH but the same gentle technique is best practice.

For the underlying reconstitution math (concentration calculations, syringe unit conversions, multi-strength reference tables), see our generalised reconstitution math guide and the dedicated BAC water guide.

Storage and stability

• Lyophilised vial (unopened): 2–8 °C refrigerated; manufacturer-claimed stability 24+ months. Long-term freezer storage at −20 °C extends shelf life further; freeze-thaw cycles should be minimised.
• Reconstituted vial: 2–8 °C; use within 28 days. The 16-amino-acid fragment is more stable in solution than the 191-AA recombinant biologic.
• Light protection: Store in original carton or opaque box.
• Transport: Cold-chain preferred but the fragment tolerates brief room-temperature transit better than recombinant somatropin — see our peptide storage and cold-chain protocol.

Injection technique

Subcutaneous injection is standard. Use 29G or 31G insulin syringes, ½-inch needle. Common research-protocol sites: abdominal wall (avoiding 2 cm around the umbilicus), lateral thigh, upper outer arm. Rotate sites to minimise local irritation. Intramuscular administration is not standard and offers no documented advantage; intranasal administration is not viable for this molecule due to size and degradation kinetics. For deeper coverage of route trade-offs, see peptide injection routes guide.

Timing in research protocols

Published research and biohacker protocols typically use one of three timing patterns:

• Twice-daily fasted-window: 250 mcg pre-breakfast (fasted state) + 250 mcg pre-bed. Rationale: capture endogenous lipolysis peaks (fasted morning and overnight) and amplify them.
• Single morning dose: 500 mcg pre-breakfast fasted. Simpler adherence; some loss of pre-bed window.
• Pre-workout dose: 500 mcg 30–60 minutes before resistance training. Rationale: combine training-induced catecholamine peak with peptide-mediated lipolysis amplification.

Evaluating a Certificate of Analysis (COA)

Lot-quality verification matters as much for HGH Fragment 176-191 as for any research peptide. The 16-amino-acid fragment is synthesised by solid-phase peptide synthesis (Fmoc strategy), and synthesis byproducts — incomplete couplings, deletion sequences, oxidised residues — can accumulate without rigorous purification. A legitimate batch-specific COA should document:

• Purity by RP-HPLC: ≥98% main peak. Below 96% rejects the lot.
• Identity by mass spectrometry: Observed molecular weight ≈1817 Da (this is the expected exact mass).
• Sequence verification: N-terminal sequencing (Edman degradation) or MS/MS confirming the 176-191 sequence.
• Bacterial endotoxin: <1 EU/mg (LAL test).
• Residual solvent: <0.5% TFA, <0.1% acetonitrile (from purification).
• Counter-ion content: Acetate or TFA salt form noted; net peptide content stated.

A COA missing any of those rows is incomplete documentation, not a quality certificate.

Frequently Asked Questions

Is HGH Fragment 176-191 the same as HGH?

No — and this is the single most-misunderstood point in the entire peptide-research space. HGH Fragment 176-191 is a 16-amino-acid synthetic peptide whose sequence matches the C-terminal tail of full-length growth hormone. The full hormone is a 191-amino-acid recombinant protein that binds GH receptors and stimulates IGF-1 production; the 16-mer fragment does neither. They share sequence but not pharmacology. If a product claims that “HGH Fragment 176-191 gives you HGH benefits,” it’s selling either a misunderstanding or a counterfeit.

Will HGH Fragment 176-191 cause my IGF-1 to rise?

No — and this is the single biggest experimental and clinical advantage over full-length GH. Across multiple published preclinical studies and the AOD-9604 human Phase 2b safety data, serial serum IGF-1 measurements have remained at baseline. That is the entire premise of the molecule’s existence in the research catalogue. If a researcher needs to study GH-related fat-loss biology without IGF-1 confounders, the fragment is the only realistic tool.

How does HGH Fragment 176-191 differ from AOD-9604?

Structurally: AOD-9604 carries an extra N-terminal tyrosine residue (Tyr-hGH 177-191). Functionally: both engage the same proposed lipolytic mechanism; AOD-9604 has been through formal human Phase 2b clinical trials (with mixed efficacy results); HGH Fragment 176-191 has not. For research-citation purposes the two are not interchangeable — Metabolic Pharmaceuticals’ published trial data applies specifically to AOD-9604. For broader mechanistic research questions, the two molecules can substitute. We carry both: HGH Fragment 176-191 and AOD-9604.

How long until I see fat-loss effects from HGH Fragment 176-191?

In human research protocols and biohacker self-reports, measurable reductions in body fat percentage typically appear over 8–12 week dosing windows when paired with calorie-restricted diets and standard exercise. The AOD-9604 Phase 2b trial showed approximately 2 kg of mean weight loss over 24 weeks — modest in absolute magnitude, not statistically significant vs placebo at the primary endpoint, but clean in safety profile. Researchers approaching this molecule expecting GLP-1-magnitude weight loss will be disappointed; researchers approaching it for clean lipolytic isolation will get what they came for.

Can HGH Fragment 176-191 cause insulin resistance?

No — and this is the second major distinction from full-length GH. The classical “diabetogenic” effect of GH (insulin antagonism in liver and skeletal muscle) is mediated by the parent hormone’s interactions with GH receptors in those tissues. The 16-amino-acid fragment lacks the structural epitopes for GH receptor binding, and serial fasting glucose / HOMA-IR / oral glucose tolerance test measurements across published preclinical and AOD-9604 human-trial data show no insulin resistance signal. This makes the fragment compatible with research subjects who have pre-existing insulin resistance, which would be a contraindication for full-length GH.

Can HGH Fragment 176-191 be stacked with other peptides?

Yes, and this is one of its strongest practical use cases. Common research stacks include HGH Frag + GHRP-2/6/Ipamorelin (the peptide adds peripheral adipose-direct lipolysis to a centrally-driven GH pulse), HGH Frag + GLP-1 agonist (peripheral fragment mechanism complements central appetite-suppression mechanism), and HGH Frag + standalone calorie restriction protocols. The fragment doesn’t compete at the GH receptor or perturb pituitary feedback, which is why it stacks cleanly. See our best peptides for fat loss for stack-design considerations.

Does HGH Fragment 176-191 build muscle?

No, and this is by design. The growth-promoting and lean-mass-building functions of full-length growth hormone reside in the N-terminal portion of the molecule (broadly residues 1–99) — not in the 176-191 C-terminal tail used in this fragment. Researchers wanting both fat loss and lean-mass gain in the same protocol need either full-length HGH 191AA or a pituitary-stimulator approach like CJC-1295 + Ipamorelin.

Can I take HGH Fragment 176-191 orally or as a nasal spray?

No. As a 16-amino-acid peptide, it is degraded by gastric proteases on oral ingestion and shows poor mucosal absorption via the nasal route. Subcutaneous injection is the only research-validated administration route. Products marketed as “oral HGH spray” or “nasal HGH fragment” do not deliver bioavailable peptide and should not be confused with the legitimate injectable form.

The Bottom Line

HGH Fragment 176-191 occupies a precise and useful niche in the research-peptide catalogue: it isolates the lipolytic activity of growth hormone biology from the broader GH/IGF-1 cascade. That separation is its entire reason for existing. For researchers who need to study or activate adipocyte lipolysis without simultaneously raising IGF-1, suppressing insulin sensitivity, or stimulating tissue growth, the 16-amino-acid C-terminal fragment is the cleanest single molecule available.

The fragment is not “weaker HGH” — that framing fundamentally misunderstands its pharmacology. It engages a different receptor (β3-adrenergic-like), produces a different physiological outcome (selective lipolysis without growth signalling), and carries a meaningfully different side-effect profile (none of the classic GH-cascade adverse effects). It is also not, on the available human clinical evidence, a magnitude-weight-loss drug — the AOD-9604 Phase 2b data showed modest, statistically-non-significant kilogram reductions. Researchers who frame it as a mechanism-isolation tool rather than a weight-loss therapeutic get accurate expectations.

Explore our research-grade HGH Fragment 176-191 with batch COA documentation, or compare against the structurally related AOD-9604 (Tyr-hGH 177-191) when citing Metabolic Pharmaceuticals trial protocols. For the broader fat-loss research landscape, see the best peptides for fat loss hub; for the broader GH context, see our growth hormone peptides hub and our companion guide to recombinant HGH 191AA. The full peptide catalogue covers complementary research compounds including 5-Amino-1MQ, Adipotide, and downstream effectors like IGF-1 LR3.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.